Abstract
The concept of different genetic pathways leading to glioblastoma multiforme (GBM) has gained considerable acceptance, and two major groups are now described, primary or de novo GBM and secondary GBM. The present study was undertaken to elucidate whether additional pathways exist and to determine whether there is any correlation between these different variants and clinical parameters, such as age, duration of symptoms, and outcome. For this purpose, immunophenotyping was performed to study the simultaneous expression of p53 protein and epidermal growth factor receptor (EGFR) in 58 cases of adult supratentorial GBM. By this method, four variants of GBM could be distinguished: 34% were p53 positive only, 38% were EGFR positive only, 14% were double negative (p53 negative/EGFR negative), and 14% were double positive (p53 positive/EGFR positive). Interestingly, all nine cases of secondary GBM in which there was clinical and histological evidence of progression from a preexisting low-grade lesion were p53 positive. Differences were observed with regard to the age distribution of the four variants, in that the p53 negative/EGFR negative tumors occurred most frequently in the younger age group (21–40 years). In the elderly group (61–80 years), two-thirds of the tumors were p53 negative/EGFR positive primary GBMs, and no case of the double positive or double negative variant was encountered. The differences in duration of symptoms and symptom-free survival according to age group and genetic subset were not statistically significant. There were no differences in outcome within each age category for any GBM variant, although the longest mean symptom-free survival was noted among patients aged 41–60 years with the p53 positive/EGFR negative variant. This study therefore indicates that at least four subsets of GBM exist, but despite different genotypes, the biologic behavior remains similar. Other genetic alterations therefore need to be investigated to identify prognostic makers.
Similar content being viewed by others
References
Kleihues P, Burger PC, Collins VP, et al (2000) Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumors of the nervous system. WHO classification of tumors International Agency for Research on Cancer, Lyon, pp 29–39
Newcomb EW, Cohen H, Lee SR, et al (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655–667
Lang FF, Miller DC, Koslow M, et al (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81:427–436
Ohgaki H, Schauble B, zur Hausen A et al (1995) Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427:113–118
Hayashi Y, Ueki K, Waha A, et al (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7:871–875
von Deimling A, von Ammon K, Schoenfeld D, et al (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19–26
van Meyel DJ, Amsay DA, Casson AG, et al (1994) p53 mutation, expression and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 86:1011–1017
Chozick BS, Weicker ME, Pezzullo JC, et al (1994) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73:406–415
Reifenberger J, Ring GU, Gies U, et al (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 7:822–831
von Deimling A, Louis DN, Weistler OD (1995) Molecular pathways in formation of gliomas. Glia 15:328–338
Watanabe K, Tachibana O, Sato K, et al (1997) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217–224
Louis DN (1997) A molecular genetic model of astrocytoma histopathology. Brain Pathol 7:755–764
Kleihues P, Ohgaki H (1997) Genetics of glioma progression and the distribution of primary and secondary glioblastomas. Brain Pathol 7:1131–1136
Louis DN, Gusella JF (1995) A tiger behind many doors: multiple genetic pathways to malignant gliomas. Trends Genet 11:412–415
Sung T, Miller DC, Hayes RL (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10:249–259
Chen Y, Ng H-K, Zhang S-F, et al (1999) Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 30:1284–1290
Litofsky NS, Hinton D, Raffel C (1994) The lack of role of p53 in astrocytomas in paediatric patients. Neurosurgery 34:967–973
Orellana C, Hernandez-Marti M, Marinez F, et al (1998) Paediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations. Cancer Genet Cytogenet 102:93–99
Pollack IF, Hamilton RL, Finkelstein SD et al (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57:304–309
Sure U, Ruedi D, Tachibana O, et al, (1997) Determinatio of p53 mutations, EGFR expression and loss of p16 expression in paediatric GBM. J Neuropathol Exp Neurol 56:782–789
Cavenee WK, Furnari FB, Nagana M, et al (2000) Diffusely infiltrating astrocytomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumors of the nervous system. WHO classification of tumors. International Agency for Research on Cancer. Lyon, pp 10–21
Kleihues P, Ohgaki H (1998) Subsets of glioblastoma: clinical and histological vs. genetic typing. Brain Pathol 18:667–668 (editorial)
Rasheed BK, McLendon RE, Herndon JE, et al (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1230
Tohma Y, Gratas C, Biernat W, et al (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57:684–689
Wong AJ, Bigner SH, Bigner DD, et al (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899–6903
Louis DN (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11–21
Louis DN, von Deimling A, Chung RY, et al (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31–38
Newcomb EW, Madonia WJ, Pisharody S, et al (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3:229–235
Sarkar C, Rathore A, Chattopadhyay P, et al (2000) Role of 17p13.3 chromosomal region in determining p53 protein immunopositivity in human astrocytic tumors. Pathology 32:84–88
Chattopadhyay P, Rathore A, Mathur M, et al (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene 15:871–874
Sarkar C, Ralte AM, Sharma MC, et al (2002) Recurrent astrocytic tumors—a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 16:335–342
Dropcho EJ, Soong SJ (1996) The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case control study. Neurology 47:684–690
Wales MM, Biel MA, el Deiry W, et al (1995) p53 activates expression of HIC-1, a new candidate tumor suppressor gene in 17p13.3. Nat Med 1:570–571
Schulz D, Vanderveer L, Berman DB, et al (1996) Identification of two candidate tumor suppressor genes in chromosome 17p13.3. Cancer Res 56:1997–2002
Sarkar C, Chattopadhyay P, Ralte AM, et al (2003) Loss of heterozygosity of a locus in the chromosomal region 17p13.3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genet Cytogenet 15:156–164
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarkar, C., Sinha, S., Sharma, M.C. et al. Supratentorial glioblastoma in adults: Identification of subsets and their clinical correlation. Brain Tumor Pathol 21, 7–12 (2004). https://doi.org/10.1007/BF02482170
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02482170